Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)

Melanoma Management

James Sun¹  Jonathan S Zager¹  Brian R Gastman²  Lucy McCahon²  Elizabeth I Buchbinder³  Michele Nanni⁴  Igor Puzanov⁴  James M Lewis⁵  Richard D Carvajal⁶  Shahnaz Singh-Kandah⁶  Anupam M Desai⁷  Rubina Ismail⁸  Carrie M Nielson⁸  Leon Raskin⁸ 

[1] 1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA;2Department of Plastic Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA;3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA;4Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14203, USA;5Department of Surgical Oncology, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA;6Department of Medical Oncology, Columbia University Irving Medical Center, New York, NY 37996, USA;7Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA;8Amgen Inc., Thousand Oaks, CA 91320, USA;

关键词: combination therapy;    immunotherapy;    metastatic melanoma;    oncolytic virus;    real-world evidence;    talimogene laherparepvec;   

DOI  :  10.2217/mmt-2020-0005

来源: DOAJ

【 摘 要 】

Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization. Materials & methods: A retrospective review of T-VEC use from 1 January 2017 and 31 March 2018 for melanoma patients was conducted at seven US institutions. Results: Among 83 patients, three categories of T-VEC and anti-PD-1 therapy were identified: T-VEC used without anti-PD-1 (n = 29, 35%), T-VEC after anti-PD-1-based therapy (n = 22, 27%) and concurrent T-VEC and anti-PD-1-based therapy (n = 32, 39%). 25% of patients discontinued T-VEC therapy due to no remaining injectable lesions, 37% discontinued T-VEC due to progressive disease. Discontinuation of T-VEC did not differ by anti-PD-1-based therapy use or timing. Conclusion: In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.

【 授权许可】

Unknown